Sugi Predict

Sugi Predict / Compounds / SCHEMBL7892155

SCHEMBL7892155

SCHEMBL7892155

COc1ccc(S(=O)(=O)NC(=O)C(C)C)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.66
▸ NPSR1 Q6W5P4 1/20 0.60
▸ MMP2 P08253 4/20 0.59
▸ MMP1 P03956 3/20 0.59
▸ MMP13 P45452 3/20 0.59
▸ MMP9 P14780 3/20 0.59
▸ MMP8 P22894 2/20 0.59
▸ CA1 P00915 2/20 0.59
▸ CA2 P00918 2/20 0.59
▸ MEN1 O00255 1/20 0.56
▸ ALOX12 P18054 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ TAAR1 Q96RJ0 1/20 0.56
▸ CA12 O43570 2/20 0.56
▸ CA9 Q16790 2/20 0.56
▸ CA14 Q9ULX7 2/20 0.56
▸ EGFR P00533 5/20 0.54
▸ MMP3 P08254 1/20 0.54
▸ MMP7 P09237 1/20 0.54
▸ GFER P55789 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17286577 0.95 ALDH1A1 (0.60) ALDH1A1NPSR1MMP2MMP1MMP13
SCHEMBL13593970 0.84 HSD17B10 (0.53) ALDH1A1MMP2MMP1MMP13MMP9
SCHEMBL17286576 0.83 TARS1 (0.73) ALDH1A1NPSR1MMP2MMP1MMP13
SCHEMBL19627408 0.81 ALDH1A1 (0.59) ALDH1A1NPSR1MMP2MMP1MMP9
SCHEMBL30498774 0.81 FLT1 (0.56) ALDH1A1NPSR1FLT1FLT4KDR
SCHEMBL8277097 0.81 ALDH1A1 (0.72) ALDH1A1NPSR1MMP2MMP1MMP13
SCHEMBL7776386 0.81 MMP2 (0.65) ALDH1A1MMP2MMP1MMP13MMP9
SCHEMBL26282718 0.81 MMP2 (0.65) ALDH1A1MMP2MMP1MMP13MMP9
SCHEMBL6102084 0.81 HSD17B10 (0.73) ALDH1A1MMP2MMP1MMP13MMP9
SCHEMBL19627375 0.81 HRH3 (0.58) ALDH1A1MMP2MMP1MMP13MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116444420-A Small molecule inhibitor of beta-catenin/BCL 9 protein interaction and application thereof 上海医药工业研究院有限公司 2023-07-18 — — CN disclosed
US-20170333399-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 — — US disclosed
US-20170333399-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 — — US disclosed
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 — — US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 — — US disclosed
US-20110028509-A1 Sulfonamides MERCK SERONO SA (CH) 2011-02-03 — — US disclosed
US-20080176870-A1 Heterobicyclic metalloprotease inhibitors NOLTE BERT 2008-07-24 — — US disclosed
US-20080176870-A1 Heterobicyclic metalloprotease inhibitors NOLTE BERT 2008-07-24 — — US disclosed
US-20080161300-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-07-03 — — US disclosed
US-20080021024-A1 Metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-01-24 — — US disclosed
US-20080021024-A1 Metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-01-24 — — US disclosed
WO-2007139856-A2 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS, INC. (US) 2007-12-06 — — WO disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
US-20070155737-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
US-20070155737-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155737-A1 Heterobicyclic metalloprotease inhibitors ADAMTS4, ADAMTS1, ADAMTS5 ALDH1A1 3954/4885NPSR1 489/4885MMP2 22/4885
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES CFTR, PKD1, PKD2 ALDH1A1 3140/4885NPSR1 1629/4885MMP2 4158/4885
US-20080176870-A1 Heterobicyclic metalloprotease inhibitors ADAM17, ADAM8, ADAM10 ALDH1A1 2279/4885NPSR1 1145/4885MMP2 20/4885
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives SCN1A, CLIC1, CLCN2 ALDH1A1 1589/4885NPSR1 1111/4885MMP2 4804/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 ALDH1A1 1806/4885NPSR1 2352/4885MMP2 13/4885
US-20080161300-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 ALDH1A1 1806/4885NPSR1 2352/4885MMP2 13/4885
US-20170333399-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof SLC10A1, FXR1, SLC10A2 ALDH1A1 984/4885NPSR1 573/4885MMP2 3848/4885
US-20080021024-A1 Metalloprotease inhibitors MMP2, MMP9, MMP3 ALDH1A1 280/4885NPSR1 991/4885MMP2 1/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 ALDH1A1 1806/4885NPSR1 2352/4885MMP2 13/4885
US-20110028509-A1 Sulfonamides CXCR3, CXCR2, CXCR1 ALDH1A1 716/4885NPSR1 59/4885MMP2 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.